Sanofi at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Sanofi exhibits at Booth 2939 at ASH 2026 in New Orleans. Its presence centres on newly diagnosed multiple myeloma, supporting symposia on four-drug regimens, individualized treatment and bringing new evidence into community practice. It also supports symposia on individualized hemophilia care and closing knowledge gaps in immune thrombocytopenia.
| Organization | ASH 2026 Attendance |
|---|---|
Sanofi Paris, France | |
Global healthcare company developing medicines and vaccines, with teams in around 100 countries. | Booth Exhibiting at Booth 2939 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm Hemophilia at the Crossroads: New Evidence for Individualized Care Tailoring hemophilia prevention with factor replacement, factor-mimicking drugs, rebalancing agents, and gene therapy to protect joints and ease treatment burden. Symposium Fri Dec 11 3:00pm–6:00pm ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centred Care Personalizing immune thrombocytopenia care beyond platelet counts, weighing new therapies alongside fatigue, cognition, heavy periods, and quality of life. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies Choosing four-drug starting regimens for newly diagnosed myeloma, using residual disease tests to guide therapy, and managing new side effects. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 3:00pm–6:00pm Quadruplet Therapy in NDMM: Interpreting the Data, Applying the Evidence Tailoring four-drug frontline regimens for newly diagnosed myeloma using residual disease testing, transplant criteria, and new ways of giving treatment. Symposium Fri Dec 11 11:00am–2:00pm Transforming Care for Newly-Diagnosed Multiple Myeloma: Integrating Evidence-Based Innovation into Community Practice Newly diagnosed multiple myeloma care in community clinics, using frailty assessment, dose adjustment to protect quality of life, and new drug formulations. |
Instantly find 20 buyers from Sanofi
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction